PsychoGenics And AstraZeneca Enter Agreement To Identify New Treatments For Central Nervous System Disorders

PsychoGenics Inc. and AstraZeneca have entered into a drug discovery and development agreement to identify compounds that are likely to be useful for the treatment of certain Central Nervous System (CNS) disorders.